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Background  and  purpose:  To  assess  effects  of  long-term  anemia  management  on  left ventricular  hyper-
trophy  in  patients  with  chronic  kidney  disease  (CKD)  not  on  dialysis,  we  performed  secondary  outcome
analyses  of  a randomized  controlled  study  that evaluated  effects  of anemia  management  with  erythro-
poiesis  stimulating  agents  in  this  population.
Methods  and  subjects:  Subjects  [hemoglobin  (Hb)  < 10.0  g/dL, 2.0  ≤  serum  creatinine  < 6.0 mg/dL]  were
randomized  either  to high  Hb  (11.0  ≤ target  Hb  ≤ 13.0  g/dL  with  darbepoetin  alfa),  or to low  Hb group
(9.0  ≤  target  Hb  ≤ 11.0 g/dL with  recombinant  human  erythropoietin),  and followed  up  to  48  weeks.  Data
from  echocardiographic  evaluation  and  values  of  neurohumoral  factors  associated  with  heart  failure  were
assessed  in  subjects  whose  data  were  evaluable  both  at the  baseline  and  at the  end  point.
Results:  The  high  Hb  group  achieved  target  range  Hb  levels  (12.1  ±  1.1  g/dL,  at  32  weeks,  N =  111),  which
was  signiﬁcantly  higher  (p <  0.001)  than the  low  Hb  group  (N  = 95).  Though  blood  pressure  and  renal
function  changes  were  similar  between  the  groups,  left  ventricular  diastolic  dimension  was signiﬁcantly
decreased  only  in  the  high  Hb  group  (p < 0.001),  and the  change  in  left  ventricular  mass  index  (LVMI)
correlated  coarsely  but signiﬁcantly  with  the  achieved  Hb  levels  (r =  0.147,  p =  0.032).  The  higher  Hb
levels  were  associated  with  greater  reduction  in LVMI  and  left  ventricular  wall  thickness,  and  the  lower
Hb  levels  with  the greater  increase  in human  arterial-  or brain  natriuretic  polypeptide  levels.
Conclusions:  Anemia  correction  targeting  modestly  higher  Hb levels  better  preserves  cardiac  function  in
CKD  patients  not  on dialysis.
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Chronic kidney disease (CKD) is an independent risk factor for
ardiovascular disease (CVD), and the risk of CVD increases as
lomerular ﬁltration rate (GFR) decreases. A prospective analy-
is showed that CKD is a signiﬁcant risk factor for CVD also in
he general Japanese population [1–3]. Furthermore, CKD patients
ith anemia are at a greater risk of developing CVD. Observa-
ional studies revealed that anemia or left ventricular hypertrophy
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(LVH) associated with CKD is an additional risk for CKD and
total mortality [4,5]. Cardio-renal anemia syndrome (CRA syn-
drome) is another complication, in which CKD, chronic heart
failure (CHF), and anemia can cause or be caused by the oth-
ers, or act as risk factors for each other [6,7]. As CKD progresses,
the patients may  develop anemia. If appropriate anemia manage-
ment breaks the vicious cycle of CRA syndrome, the progression
of each disease can be prevented. Approximately 75% of CKD
patients are complicated with LVH at the initiation of renal replace-
ment therapy, and have various complications of CVD such as
CHF, coronary artery disease, or peripheral vascular disease [8–10].
The importance of anemia management from the early stages of
CKD has been emphasized and several controlled studies have
been conducted to determine the reasonable target levels in cor-
recting anemia [11–15]. However, the optimal target levels for
vier Ltd. All rights reserved.
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nemia correction remain controversial in regard to reducing
he risk of developing CVD and improving the prognosis in CKD
atients.
In Japan, recombinant human erythropoietin (rHuEPO) has been
sed in clinical settings since 1990. Because periodic erythro-
yte transfusion was the only therapeutic choice for CKD patients
ith anemia before the introduction of rHuEPO, anemia correc-
ion with rHuEPO dramatically decreased the number of CKD
atients requiring erythrocyte transfusion and greatly improved
atients’ quality of life, as well as their prognosis. The hemoglobin
Hb) levels for anemia correction with rHuEPO at around 10 g/dL
ave been recommended. However, in a late phase II clinical
tudy of darbepoetin alpha, LVH and myocardial stress were
igniﬁcantly reduced in CKD patients not on dialysis whose
b levels were increased to greater than 11.0 g/dL in16 weeks
16,17]. In the present study, we further analyzed the secondary
utcomes of a 48-week, randomized, controlled study [17] to deter-
ine whether maintaining target hemoglobin (Hb) levels higher
han those achieved by conventional anemia treatment levels
11.0 ≤ Hb ≤ 13.0 g/dL and 9.0 ≤ Hb ≤ 11.0 g/dL, respectively) bene-
cially affects LVH and cardiac overload in patients with CKD not on
ialysis.
ethods
tudy design and patients
The present study is a sub-analysis focused on cardiac func-
ions in study subjects of a multicenter open-label randomized
ontrolled study involving 79 medical centers conducted between
ovember 2005 and April 2007 [17]. In subsets of the study popu-
ation that were followed up for 48 weeks, data regarding cardiac
unctions were assessed in the present study comparing values at
aseline and at 32 weeks after starting erythropoiesis stimulating
gent (ESA: darbepoietin alfa or rHuEPO) treatment.
The protocol of the main study was approved by institutional
eview boards of all the participating medical centers. All the par-
icipants in the study gave written informed consent.
The detailed protocol of the study was described elsewhere [17],
nd a brief summary of the protocol is presented here.
The study included patients with CKD not on dialysis, whose
b levels were less than 10.0 g/dL, and whose serum creatinine
Cr) levels were ≥2.0 mg/dL and <6.0 mg/dL or creatinine clearance
Ccr) levels ≤30.0 mL/min.
The enrolled patients were randomized to either of the two
reatment groups: the high Hb group, in which darbepoetin alfa
as administered to achieve a target Hb level of ≥11.0 g/dL and
13.0 g/dL, or the low Hb group, in which rHuEPO was administered
o reach a target Hb level of ≥9.0 g/dL and ≤11.0 g/dL. Randomiza-
ion was performed using the minimization method with Hb levels
<9.0 g/dL or ≥9.0 g/dL), serum Cr levels (<4.0 mg/dL or ≥4.0 mg/dL),
nd the presence or absence of diabetes mellitus, and participating
edical centers as adjustment factors.
Subjects in the high Hb group started with subcutaneous dar-
epoetin alfa 60 g every two weeks. After reaching the target
b level (11.0 ≤ Hb ≤ 13.0 g/dL), the Hb level was maintained with
ubcutaneous darbepoetin alpha every 2 or 4 weeks. Subjects in
he low Hb group started to receive subcutaneous rHuEPO at a
ose of 6000 IU once a week, in accordance with the dosage and
dministration approved in Japan. After reaching the target Hb
evel (9.0 ≤ Hb ≤ 11.0 g/dL), the Hb level was maintained with sub-
utaneous rHuEPO once a week or every 2 weeks for 48 weeks.
uring the study, a combination of supplemental iron as neces-
ary, blood pressure control, and dietary control for salt and protein
ntake were also administered as described in detail elsewhere
17].iology 62 (2013) 249–256
Measurement of cardiac function and other examinations
Echocardiography, assay for neurohumoral factors [serum
human brain natriuretic peptide (BNP) and human atrial natri-
uretic peptide (hANP)], and chest X-ray were performed to evaluate
cardiac function at baseline and 32 weeks or at discontinuation
of the treatment. Blood pressure, heart rate, complete blood cell
counts, and blood chemistry were assessed every 2 or 4 weeks
depending on the injection schedule of darbepoetin alpha or
rHuEPO.
Since M-mode imaging was necessary for echocardiographic
measurements, the following patients with factors that might
hamper appropriate image acquisition and/or its evaluation were
excluded.
Those who  discontinued the study earlier than 16 weeks after
the start of treatment were also excluded from the evaluation.
(1) Patients with pericardial disease or myocarditis.
(2) Patients with multiple ventricular premature contractions.
(3) Patients with atrial ﬁbrillation.
(4) Patients with myocardial infarction.
(5) Patients with organic valvular disease or with moderate to
severe valvular regurgitation.
(6) Patients with hypertrophic cardiomyopathy.
(7) Patients with arteriovenous ﬁstula.
At each medical center, the following ﬁve types of echocardio-
grams were obtained: left ventricular M-mode echocardiogram and
the end-diastolic/end-systolic long and short axis cross-sectional
images of the left ventricle, and all the images were collected
and evaluated by an external evaluation committee consisting of
3 cardiologists. Two  cardiologists ﬁrst evaluated the quality of
echocardiograms, and then measured left ventricular end diastolic
dimension (LVDd), left ventricular end systolic dimension (LVDs),
interventricular septal thickness (IVST), and posterior wall thick-
ness (PWT) by left ventricular M-mode echocardiography using
the ASE method (American Society of Echocardiography leading
edge recommendations) [18]. The mean value of the measurement
results by two  cardiologists was  used as the ﬁnal measurement
value. When the two measurements disagree, the results were dis-
cussed with a third cardiologist and the ﬁnal decision reﬂected
the consensus of all three cardiologists. In order to avoid bias, all
evaluations and measurements were conducted after masking the
treatment groups, the timing of examinations, and patient charac-
teristics.
From the measured left ventricular parameters, left ven-
tricular mass was  calculated using Devereux’s formula [19]:
0.8 × {1.04 × [(LVDd + IVST + PWT)3−LVDd3]} + 0.6, which was
divided by body surface area to obtain LVMI. To assess left ventri-
cular systolic function, left ventricular ejection fraction (LVEF) was
calculated using left ventricular volume by the Teichholz method.
Analyses
Patient characteristics
Summary statistics were obtained and compared by two-sample
t-test for continuous variables and by 2 test for frequencies of
nominal variables.
Comparison of cardiac function indices between the high- and
low-Hb groups
Cardiac function was analyzed in patients whose echocardio-
grams were obtained and evaluable both before and after the
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treatment in this study. Parameters chosen for the study were
obtained at the start of treatment (baseline) and when ﬁnal
assessment of LVMI was performed (end point). Mean changes
and 95% conﬁdence intervals were calculated for each group
between the baseline and end point values, and differences
between the two groups were analyzed with a two-sample t-test.
Within-group comparison of changes in LVMI and other param-
eters from baseline to end point was conducted by one-sample
t-test.
Correlation between achieved Hb levels and changes in cardiac
function indices (LVMI and other parameters)
Data from the two groups were combined irrespective of the
treatment received and divided into ﬁve categories based on
Hb levels at the end point (Hb < 10.0 g/dL, 10.0 ≤ Hb < 11.0 g/dL,
11.0 ≤ Hb < 12.0 g/dL, 12.0 ≤ Hb < 13.0 g/dL, Hb ≥ 13.0 g/dL) to ana-
lyze the relationship between the changes in cardiac function
parameters and Hb levels. Correlation between the change in
the LVMI and the Hb levels at the endpoint was also assessed.
Summary statistics and 95% conﬁdence intervals of the various
parameters studied in each Hb category were calculated. An anal-
ysis of covariance was  performed with LVMI at the baseline as
a covariate, and the adjusted mean and 95% conﬁdence inter-
val were calculated. Similar analyses were performed for other
parameters. In addition, to evaluate correlation between the end
point Hb levels and cardiac function indices such as changes in
LVMI, contribution of the changes in Hb levels to each param-
eter of cardiac functions was determined by a linear regression
model using cardiac function indices at baseline as a covariate.
Data were presented as mean ± standard deviation. If interval esti-
mates were required, two-sided 95% conﬁdence intervals were
calculated. Two-sided p-values of 0.05 were considered as signif-
icant.
All analyses were performed with SAS (Cary, NC, USA).
esults
atients and baseline characteristics
A total of 322 patients identiﬁed as being eligible for the present
tudy were randomized in a ratio of 1:1 to either the high or low
b group. Of the 322 patients (161 in the high Hb group and 161
n the low Hb group), echocardiograms at the start of study were
vailable in 244 patients, excluding 78 patients who  discontinued
he study earlier than 16 weeks after starting the treatment, who
ad a disease that might prevent appropriate M-mode echocar-
iographic evaluation, or those who did not have all the required
easurements at the time of baseline evaluation. Thereafter,
chocardiography was performed at 32 weeks or at study dis-
ontinuation. Excluding 38 patients whose cardiac measurements
ere not available, the ﬁnal analysis for cardiac function in the
resent study included 206 patients (111 in the high Hb group and
5 in the low Hb group), whose echocardiography at both 0 week
baseline) and post-treatment were evaluable (Fig. 1). Echocar-
iograms were not evaluated in a total of 116 (36.0%) patients,
ue either to unclear images, inappropriate echo beam direction,
ericardial effusion, discontinuation earlier than 16 weeks after
tarting the treatment, or no examination performed. Thirty six
ases were discontinued after 16 weeks, including 12 cases in the
igh Hb group and 24 cases in the low Hb group due to introduction
f hemodialysis (15 cases), adverse events (7 cases), inadequate
esponse to darbepoetin alpha or rHuEPO (5 cases), discontinu-
tion of drug because of excess response (7 cases), or voluntaryiology 62 (2013) 249–256 251
withdrawal (2 cases). These 36 discontinued cases after 16 weeks,
whose observation period was  21.7 ± 4.6 weeks, were included for
analysis using the last measurement at the discontinuation.
No signiﬁcant difference between the groups was  observed in all
the baseline patient characteristics other than gender and transfer-
rin saturation (Table 1). All the other baseline parameters including
Hb level, the serum Cr level, and estimated glomerular ﬁltration rate
(eGFR) were not different between the two groups. No imbalance
was detected between the groups in past and present history of
CVD, including angina, atrial ﬁbrillation, congestive heart failure,
myocardial infarction, hypertension, and cerebral infarction.
Time course of Hb levels, blood pressure, and kidney function
Fig. 2 shows the changes in Hb levels, blood pressure, and eGFR
during the study. As shown in Fig. 2, subjects in the high Hb
group achieved the lower limit of the target Hb ranges, 11.0 g/dL,
by 8 weeks, and thereafter remained within the target Hb range
(11.0–13.0 g/dL) for 32 weeks. In the low Hb group, the Hb level
remained within the target Hb range (9.0–11.0 g/dL) from the start
to the end of the treatment. The baseline Hb levels of the two  groups
were mostly equivalent (9.3 ± 0.8 g/dL), while the Hb levels at the
echocardiogram measurements (32 weeks) of high Hb group were
higher (12.0 ± 1.2 g/dL) than in the low Hb group (10.1 ± 1.0 g/dL,
Fig. 2A). Blood pressure did not change signiﬁcantly, and eGFR
showed a tendency to decrease during the study, and showed sim-
ilar time course of changes in both groups (Fig. 2B and C).
Changes in cardiac function indices
Echocardiographic parameters
Echocardiographic parameters before and after the study treat-
ment are summarized in Table 2. LVMI and left ventricular wall
thickness (IVST + PWT) were signiﬁcantly decreased only in the
high Hb group. LVMI did not change from baseline in the low Hb
group, whereas it decreased by 7.8 g/m2 in the high Hb group,
and the changes in LVMI were statistically signiﬁcant between the
groups (p = 0.009, Table 2B). As shown in Table 2B, the decrease
in left ventricular wall thickness (IVST + PWT) as well as that of
PWT  was greater in the high Hb group, and it was  also statistically
signiﬁcant between the groups (p = 0.023 and 0.016, respectively).
There was  no difference in the changes of other echocardiographic
parameters (Table 2B).
Cardiothoracic ratio (CTR) did not show any difference between
the two groups, either before or after the treatment. Also, there
was no signiﬁcant difference in changes of heart rates between the
two groups (0.9 ± 11.1 and −1.5 ± 9.5/min, high and low Hb groups,
respectively).
Neurohumoral factors
BNP levels increased by 23.3 pg/mL only in the low Hb group
(p = 0.03), whereas h-ANP was  unchanged in both groups (Table 2).
Change in levels of BNP from baseline to the 32nd week signiﬁcantly
correlated with the changes in LVMI (p = 0.014). Change in levels of
h-ANP also showed a weak trend to associate with the changes in
LVMI, but was  not found to be statistically signiﬁcant (p = 0.092).
Correlation between the achieved Hb levels and changes in
cardiac function indices (LVMI and other parameters)
Hb levels achieved after the 32-week treatment correlated
coarsely but signiﬁcantly with the change in LVMI (r = 0.147,
p = 0.034). Fig. 3 shows that the changes in LVDd, hANP, or BNP
decreased as Hb levels increased (p = 0.008, p < 0.001 and p = 0.045).
However, no signiﬁcant relationships between the changes in EF
with Hb levels were observed.
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iscontinuation) were available, were included in the present analyses. A total of
chocardiographic evaluation or missing M-mode echocardiographic measurement
elationship between baseline LVMI and improvement in LVMI by
nemia correction
Fig. 4 shows the change in LVMI in each group that was
ategorized based on the baseline LVMI (LVMI < 100 g/m2, 100 ≤
VMI < 130 g/m2, 130 ≤ LVMI < 160 g/m2, and LVMI ≥ 160 g/m2).
ecrease in LVMI was greater in the more severe LVH category.
elationship between changes in LVMI and kidney function
Decrease in LVMI after the 32-week treatment also showed sig-
iﬁcant correlation with changes in kidney functions determined
s serum creatinine levels or eGFR (p = 0.007, p = 0.049 between the
hanges of LVMI and serum creatinine levels or eGER, respectively).iscussion
The present study showed, in patients with CKD not on dialy-
is, that correcting anemia with target Hb levels at 11.0–13.0 g/dLhose echocardiographic measurements for both baseline and at 32 weeks (or at
patients were excluded for either a disease history that could inﬂuence M-mode
 hemoglobin; LVMI, left ventricular mass index.
decreases LVMI more signiﬁcantly compared to the conventional
treatment level of 9.0–11.0 g/dL. The present results also demon-
strated that, regardless of the treatment method, higher Hb level
achieved was associated with greater reduction of LVH and lesser
production of neurohumoral factors that reﬂect ventricular over-
load. Patients with more severe baseline LVH responded more
signiﬁcantly with decreases in the LVMI. Together, the present
results suggest that anemia correction to modestly higher Hb levels
in CKD patients not on dialysis could reduce incidence of LVH.
Recently, four large-scale randomized controlled studies
(ACORD, CHOIR, CREATE, and TREAT) were conducted to deter-
mine the effects of Hb level normalization in patients with CKD
not on dialysis in association with the risk of developing LVH
or CVD [13–15,20]. All four studies used higher target levels
than the present study (more than 13.0 g/dL in the TREAT study,
13.0–15.0 g/dL in the ACORD study, 13.5 g/dL in the CHOIR study,
and 13.0–15.0 g/dL in the CREATE study, as target Hb levels). In any
of these studies, no risk reduction for the development of LVH or
CVD was  observed in high Hb groups compared to low Hb groups
(Hb level of approximately 11.0 g/dL). Furthermore the TREAT study
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Table  1
Subject characteristics.
Characteristic High Hb group
(n = 111)
Low Hb group
(n = 95)
p-Value
Age (yr) 63.6 ± 12.4 61.4 ± 11.0 0.173
Female sex – no. of patients (%) 51 (45.9) 57 (60.0) 0.044
Cause of chronic kidney disease
– no. of patients (%)
0.717
Glomerulonephritis 55 (49.5) 46 (48.4)
Diabetic nephropathy 22 (19.8) 23 (24.2)
Pyelonephritis 0 (0.0) 1 (1.1)
Polycystic kidney disease 5 (4.5) 2 (2.1)
Nephrosclerosis 15 (13.5) 10 (10.5)
Other 14 (12.6) 13 (13.7)
Cardiovascular history – no. of
patients (%)
106 (95.5) 92 (96.8) 0.618
Weight (kg) 56.6 ± 10.9 56.2 ± 11.2 0.820
Height (cm) 159.0 ± 9.3 157.6 ± 7.9 0.279
Transferrin saturation (%) 32.9 ± 12.4 29.3 ± 11.2 0.030
Ferritin (ng/mL) 119.3 ± 122.2 107.4 ± 100.8 0.449
Creatinine (mg/dL) 3.52 ± 1.08 3.49 ± 1.08 0.845
Creatinine clearance (mL/min) 19.6 ± 7.2 19.0 ± 6.6 0.541
eGFR (mL/min/1.73 m2) 12.9 ± 4.9 12.7 ± 4.9 0.715
hANP (pg/mL) 47.8 ± 29.7 53.9 ± 37.9 0.197
BNP (pg/mL) 116.3 ± 162.6 97.5 ± 138.5 0.376
CTR  (%) 49.4 ± 5.2 49.1 ± 6.2 0.724
Hb, hemoglobin; eGFR, estimated glomerular ﬁltration rate; hANP, human atrial
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Fig. 2. Time course of hemoglobin (Hb) levels, blood pressure, and estimatedatriuretic peptide; BNP, brain natriuretic peptide; CTR, cardiothoracic ratio.
GFR was estimated according to the Modiﬁcation of Diet in Renal Disease formula.
emonstrated signiﬁcant increase in stroke in the high Hb group.
 meta-analysis of nine clinical studies in patients with CKD at
arious stages [21] also reported that patients with a target Hb
evel within the normal range (≥13.0 g/dL in seven studies and
12.0 g/dL in two studies) had higher risk of total death, shunt
hrombosis, and poor blood pressure control. These recent reports
uggested that normalization of the Hb level in patients with CKD
ot on dialysis is not necessarily beneﬁcial but rather could be detri-
ental. However, since characteristics of patients with CKD not on
ialysis and the frequency of CVD are distinct in Japanese compared
o those in Westerners, results from non-Japanese clinical stud-
es may  not be applicable to Japanese patients. In addition, the Hb
evel after achieving the target Hb in the present study was  approx-
mately 12.0 g/dL in the high Hb group (not more than 13.0 g/dL),
hich was lower than the target Hb levels in most previous studies.
he modestly high Hb target level was achieved with the protocol
hat included the rule for discontinuation of the drug.
Although several reports described that anemia correction
mproves LVMI [22], few studies investigated LVMI or LVH in a long-
erm and randomized condition. There have been a few studies
onducted in Japan, which found that anemia correction favorably
ffects cardiac function in CKD patients not on dialysis [23,24].
owever, those studies were small in sample size or retrospec-
ive assessment not a controlled comparative study with certain
arget Hb levels. The present study was originally conducted as
 long-term randomized controlled study to evaluate the effect
f the different levels of anemia correction on renal function, in
atients with CKD not on dialysis. Here, we further investigated
he long-term cardio-protective effect of anemia correction levels
n the same study population.
In patients whose Hb levels were targeted between 11.0 and
3.0 g/dL, LVMI was signiﬁcantly improved. Analysis combining the
igh and low Hb groups showed a signiﬁcant relationship between
he achieved Hb levels and LVMI improvement, suggesting that
nemia correction has a profound effect on the regression of LVH.
he higher achieved Hb level, irrespective of the treatment groups,
as also associated with the lower hANP or BNP levels. hANP
nd BNP levels reﬂect left ventricular overload [25–28]. Thus,
he observed improvement in neurohumoral factors representsglomerular ﬁltration rates (eGFR). (A) Time course of mean Hb levels. The target
Hb  level was 11.0–13.0 g/dL in the high Hb group and 9.0–11.0 g/dL in the low Hb
group. (B) Time course of mean blood pressure. Diast-BP, diastolic blood pressure;
Syst-BP, systolic blood pressure. (C) Time course of mean eGFR.
a decrease in left ventricular overload. As anemia contributes to
left ventricular overload through high output state, stimulation
of sympathetic nervous system or relative myocardial ischemia,
achieving near-normal Hb levels helps to improve the left ven-
tricular loads, as shown in the present study. The signiﬁcant
correlation detected in the present study between the levels of
Hb achieved and reduction of LVH further supports the beneﬁcial
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Table 2
Summary of echocardiography data and humoral factors of cardiac function.
High Hb group Low Hb group
Baseline
Mean ± SD
(n = 111)
End point
Mean ± SD
(n = 111)
One sample t-test Baseline
Mean ± SD (n = 95)
End point
Mean ± SD (n = 95)
One  sample t-test
(A) Baseline and end point values of markers for cardiac functions in the high- and low-Hb groups
LVDd (mm) 49.35 ± 5.49 49.42 ± 5.70 0.835 49.31 ± 5.65 49.54 ± 5.37 0.455
LVDs  (mm)  29.81 ± 6.00 29.08 ± 5.61 0.108 29.12 ± 5.81 29.02 ± 5.69 0.759
IVST  + PWT  (mm)  21.41 ± 3.35 20.45 ± 2.64 <0.001 21.16 ± 3.42 20.95 ± 3.63 0.317
IVST  (mm) 11.03 ± 1.92 10.61 ± 1.67 0.004 10.97 ± 1.92 10.85 ± 2.18 0.42
PWT  (mm)  10.39 ± 1.64 9.84 ± 1.23 <0.001 10.19 ± 1.73 10.10 ± 1.65 0.408
LVMI (g/m2) 127.7 ± 37.2 119.9 ± 30.3 <0.001 126.1 ± 35.1 126.0 ± 36.2 0.955
LVEF  (%) 64.28 ± 9.68 66.05 ± 9.36 0.059 65.72 ± 9.84 66.51 ± 8.83 0.276
BNP  (pg/mL) 116.3 ± 162.6 136.2 ± 201.7 0.119 97.5 ± 138.5 120.8 ± 174.6 0.03
hANP (pg/mL) 47.8 ± 29.7 48.9 ± 36.0 0.684 53.9 ± 37.9 56.9 ± 49.7 0.342
High Hb group
Mean ± SD (n = 111)
Low Hb group
Mean ± SD (n = 95)
Two  sample t-test
(B) Changes of cardiac function markers in the high- and low-Hb groups
LVDd (mm) 0.08 ± 3.91 0.22 ± 2.92 0.763
LVDs  (mm) −0.76 ± 4.70 −0.10 ± 3.31 0.253
IVST  + PWT  (mm) −0.96 ± 2.52 −0.21 ± 2.08 0.023
IVST  (mm)  −0.42 ± 1.50 −0.12 ± 1.44 0.152
PWT  (mm)  −0.54 ± 1.48 −0.10 ± 1.12 0.016
LVMI  (g/m2) −7.8 ± 22.4 −0.1 ± 19.3 0.009
LVEF  (%) 1.89 ± 9.82 0.79 ± 7.06 0.365
BNP  (pg/mL) 19.9 ± 133.5 23.3 ± 103.4 0.838
hANP  (pg/mL) 1.1 ± 27.3 3.0 ± 31.1 0.625
LVDd was measured at the peak of the R wave on the ECG, and LVDs were measured at the time when the interventricular septum was  located most posteriorly. IVST and
PWT  were measured at end diastole. LVMI was calculated using the measurements by Devereux’s formula. LVEF was calculated using the Teichholz method.
Measurements of markers in individual patients at the baseline were subtracted from those at the end points, and the values were compared between the two groups by the
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Hwo-sample t-test. Mean of the subtracted values are also shown.
b, hemoglobin; LVDd, left ventricular end diastolic dimension; LVDs, left ventricu
hickness; LVMI, left ventricular mass index; LVEF, left ventricular ejection fraction
ffects of anemia correction on improving LVH. Patients with
igher baseline LVMI showed more signiﬁcant decrease in the
VMI, suggesting that aggressive anemia correction would be more
ffective in patients with more advanced LVH.
LVH, preceding overt cardiac failure, is a classic risk factor for
eveloping CVD, as is anemia. Increasing the Hb levels to between
1.0 and 13.0 g/dL may  prevent increase in LVMI, and regressing
VH can eliminate the risk factors for developing CVD, implying that
ig. 3. Changes in cardiac function parameters classiﬁed into ﬁve categories according to 
n  hANP from baseline to end point by Hb levels. (C) Changes in BNP from baseline to en
b,  hemoglobin; LVMI, left ventricular mass index; hANP, human atrial natriuretic peptidd systolic dimension; IVST, interventricular septal thickness; PWT, posterior wall
 brain natriuretic peptide; hANP, human atrial natriuretic peptide.
anemia correction may  improve prognosis via two  related mech-
anisms: (1) by ameliorating anemia as an independent CVD risk
factor; and (2) by suppressing LVH as another independent risk
factor for CVD.
The present study also revealed a correlation between dete-
rioration of kidney function and increases in LVMI. Although
baseline and changes in kidney function determined by creati-
nine or eGFR were not statistically different between both groups,
Hb levels. (A) Changes in LVMI from baseline to end point by Hb levels. (B) Changes
d point by Hb levels. (D) Changes in LVDd from baseline to end point by Hb levels.
e; BNP, brain natriuretic peptide; LVDd, left ventricular end diastolic dimension.
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fter long-term follow up of this study, the renal composite
utcomes determined by time to occurrence of end-stage renal
isease (ESRD), doubling of serum creatinine or death was sig-
iﬁcantly lower in the high Hb group [29]. This may  suggest a
idney-mediated relationship between the correction of anemia
nd amelioration of cardiac function or these three functions in
riad may  interact with one another in this patient population.
Although this is a randomized prospective study, bias due to
he open-label controlled study design may  be present. To mini-
ize the bias, LVMI was evaluated by three cardiologists blinded
o treatment group, patient characteristics, and other information
or all the patients. The two groups used different drugs to achieve
he targeted Hb levels. At the time the present study was conducted,
HuEPO administration was limited not to reach an Hb level at
pproximately 12 g/dL by the Japanese health insurance system,
hile darbepoetin alfa was under investigation for its safety and
fﬁcacy and was accessible to aim higher Hb levels. Because dar-
epoetin alfa and rHuEPO share similar pharmacological proﬁles,
xcept that the former has a longer half-life, the effects on car-
iac functions observed in the present study could reasonably be
nterpreted as pure outcomes from the different Hb levels achieved.
owever, we cannot fully exclude the possibility that an unknown
ffect distinct to either of the drugs might have caused differen-
ial outcome observed in the present study, since, by the study
esign, there were substantial differences, including the Hb levels
chieved between the two groups. Use of two study drugs, though
imilar in action, is a limitation of the present study. We  hope that
ur ﬁndings that suggest beneﬁcial effects of anemia correction
ith modestly high target Hb levels would further encourage larger
tudies to justify use of either ESA to treat modestly anemic patients
ith CKD for better outcomes.
onclusionsThese results from the present study support our previous
bservation in a late phase II clinical study that increasing the
b level to at least 11.0 g/dL would reduce LVH and be cardio-
rotective in patients with CKD not on dialysis. group. The groups were classiﬁed into four categories for LVMI changes according
A long-term clinical study using harder end points such as death
or development of overt CVD is warranted to investigate the effects
of anemia correction up to the modestly high Hb level (more than
11 g/dL and less than 13 g/dL) on the prognosis of CKD patients.
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